Video
Dr. Zorn discusses 3-year data on Aquablation
Author(s):
“I think Aquablation is safe. It’s efficacious, especially in these large prostates,” says Kevin Zorn, MD, FRCSC, FACS.
Video Player is loading.
In this video, Kevin Zorn, MD, FRCSC, FACS, discusses the findings and takeaways of the study, “Aquablation for benign prostatic hyperplasia in large prostates (80-150CC): 3-year results,” which was presented during the 2021 American Urological Association annual meeting. Zorn is an associate professor of urology at the University of Montreal, Canada.
Related Videos
Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
Karyn S. Eilber, MD, shares her reaction to genitourinary syndrome of menopause guidelines
Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
Endourologist discusses shared decision-making and laser lithotripsy
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Related Content
